Corticosteroid Therapy in Acute Respiratory Distress Syndrome
- 8 July 1998
- journal article
- editorial
- Published by American Medical Association (AMA)
- Vol. 280 (2) , 182-183
- https://doi.org/10.1001/jama.280.2.182
Abstract
The annual incidence of acute respiratory distress syndrome (ARDS) has been estimated at 150000 cases in the United States.1 Although its outcome may have improved in the past 2 decades,2,3 ARDS remains associated with a very high mortality, ranging from 35% to 65% of affected patients.2,4 Severe hypoxemia (ie, an oxygenation ratio of PaO2 to fraction of inspired oxygen [FIO2] of 1 but most fatalities result from associated conditions, especially multiple organ failure and sepsis, and less commonly from intractable respiratory failure.2Keywords
This publication has 7 references indexed in Scilit:
- Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respiratory Distress Syndrome: a Randomized Controlled TrialSurvey of Anesthesiology, 1999
- Effect of a Protective-Ventilation Strategy on Mortality in the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 1998
- Biological markers of acute lung injury: prognostic and pathogenetic significance.American Journal of Respiratory and Critical Care Medicine, 1997
- The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.American Journal of Respiratory and Critical Care Medicine, 1994
- An Expanded Definition of the Adult Respiratory Distress SyndromeAmerican Review of Respiratory Disease, 1988
- High-Dose Corticosteroids in Patients with the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1987
- Early Methylprednisolone Treatment for Septic Syndrome and the Adult Respiratory Distress SyndromeChest, 1987